Market Overview:
Compounded chemotherapy medications are prescribed medications prepared by licensed pharmacies to meet treatment requirements of individual cancer patients. They provide customized chemotherapy that is tailored as per the specific needs of the patients which helps in improved treatment outcomes.
Key Takeaways:
The Global Compounding Chemotherapy Market Size was valued at US$ 10.20 Bn in 2023 and is expected to witness high growth, exhibiting CAGR of 5.3% over the forecast period, due to increasing adoption of personalized chemotherapy.
Regional analysis: North America dominated the compounding chemotherapy market in the past and is expected to continue its dominance over the forecast period. This can be attributed to rising demand for personalized medications and higher acceptance of compounding practices in the region.
Key players analysis: Key players operating in the compounding chemotherapy market are B. Braun Melsungen AG, Fagron NV, PharMEDium Services, LLC (AmerisourceBergen Corporation), Baxter International Inc., Fresenius Kabi AG, Advanced Pharma, Inc., McGuff Compounding Pharmacy Services, Inc., Central Admixture Pharmacy Services, Inc. (CAPS), Institutional Pharmacy Solutions, LLC, Wedgewood Pharmacy, Medisca Inc., Dougherty's Holdings, Inc., PharMEDium Services, LLC (AmerisourceBergen Corporation), PharMEDium Services, LLC, (AmerisourceBergen Corporation), BioScrip, Inc.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian